

# Considering TheraSphere to treat HCC

Information for your doctor



## What is TheraSphere?

TheraSphere is the market leader and first FDA-approved transarterial radiation therapy for hepatocellular carcinoma (HCC), delivering maximum damage to the tumor, sparing healthy tissue and preserving treatment options.

Backed by over 25 years of clinical data and more than 150,000 procedures worldwide, TheraSphere is an efficient and powerful treatment that safely delivers high-dose radiation, which can:

- Aid in achieving surgical candidacy
- Preserve transplant eligibility
- Support strong Overall Survival outcomes



## How does TheraSphere work?

An interventional radiologist administers TheraSphere through a microcatheter typically placed in the femoral artery. Each glass sphere delivers a highly concentrated dose of Y-90 radiation that targets the tumor. TheraSphere's unique ability to safely deliver high-dose radiation with fewer spheres allows for maximum absorbed dose and increased tumor response while minimizing damage to healthy tissue, which helps preserve future treatment options, such as surgical resection, liver transplant or systemic agents.<sup>1</sup> TheraSphere widens the field of treatment possibilities to ultimately improve patient outcomes.

## Preserve HCC treatment options

Early treatment with TheraSphere allows you to maximize your chances for tumor response. Easily delivered through a minimally invasive outpatient procedure, TheraSphere is well-tolerated by patients with minimal side effects.

Studied across all BCLC stages<sup>2</sup>

Minimally invasive outpatient procedure<sup>3</sup>

Maintains patient eligibility for future treatment



Learn more about how TheraSphere is made and how it works.

## Clinical evidence



Studied across all BCLC stages, TheraSphere is a versatile, data-backed treatment with proven clinical results.

**100%** of patients in the LEGACY study responded to TheraSphere treatment(s).<sup>2\*</sup>

**86%** three-year survival rate for patients treated with TheraSphere.<sup>2</sup>

**93%** three-year Overall Survival rate when TheraSphere helped patients reach surgery or transplant.<sup>2</sup>

**88%** demonstrated rate of best response by TheraSphere.<sup>2</sup>



## Next steps

Refer your patient to an interventional radiologist if you think TheraSphere may be an option to help treat their hepatocellular carcinoma (HCC), or scan the QR codes to learn more about TheraSphere and the treatment centers that administer it.



**View physician resources for more information about TheraSphere.**



**Find a treatment center near you for your HCC patient.**

## References

1. Lam, M., Garin, E., Maccauro, M. et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging (2022). <https://doi.org/10.1007/s00259-022-05774-0>.
2. Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study. Hepatology. 2021 Mar 19. doi: 10.1002/hep.31819.
3. Gabr, A., Kulik, L., Mouli, S., Riaz, A., Ali, R., Desai, K., Mora, R.A., Ganger, D., Maddur, H., Flamm, S., Boike, J., Moore, C., Thornburg, B., Alasadi, A., Baker, T., Borja-Cacho, D., Kataruya, N., Ladner, D.P., Caicedo, J.C., Lewandowski, R.J. and Salem, R. (2020), Liver Transplantation Following Yttrium-90 Radioembolization: 15-year Experience in 207-Patient Cohort. Hepatology. Accepted Author Manuscript. doi:10.1002/hep.31318 >=30% hepatic reserve.



**TheraSphere™ Y-90 Glass Microsphere Indications, Safety, and Warnings**

<https://www.bostonscientific.com/therasphere-indications>

# TheraSphere Referral Form



## Patient Information

Patient Name: \_\_\_\_\_

DOB: \_\_\_\_/\_\_\_\_/\_\_\_\_ Phone Number: \_\_\_\_\_

Email: \_\_\_\_\_

## Clinical Diagnosis & Eligibility

- Confirmed hepatocellular carcinoma (HCC)
- Liver-dominant disease
- Not a candidate for resection or ablation
- Portal vein thrombosis present (if applicable)
- Progression after or not candidate for TACE/systemic therapy

## Clinical Summary

Tumor Size/Burden: \_\_\_\_\_

ECOG Performance Status: \_\_\_\_\_

Most Recent Imaging (CT/MRI + Date): \_\_\_\_\_

Child-Pugh Score: \_\_\_\_\_ BCLC Stage: \_\_\_\_\_

## Referring Physician Information

Referring Physician: \_\_\_\_\_

Phone Number: \_\_\_\_\_ Email: \_\_\_\_\_